Immunocore fires up with $130m Series B

3rd March 2020

Immunotherapy company Immunocore, a spinout of a spinout, has raised $130m in its Series B round.

Immunocore, along with sister company Adaptimmune, is continuing to develop immunotherapy technologies originating from the University. It is focused on T cell receptors (TCR) therapies, which train T cells to be able to differentiate between cancerous and healthy cells, allowing them to target the former effectively.

The Series B was led by General Atlantic, and saw support from new investors CCB International, JDRF T1D Fund, Rock Springs Capital, Terra Magnum Capital Partners, and WuXi AppTec’s Corporate Venture Fund, as well as existing backers.

Press release sign up